Literature DB >> 10687223

[How we use opioid drugs on patients with neoplasms].

A Rispau Falgàs1, M Soler Vila, I García Bayo, A Vallés Plasencia, R Saladich Puig, V Martínez Alemany.   

Abstract

OBJECTIVE: To find the pattern of use of opiate drugs for treating pain in terminal cancer patients.
DESIGN: Retrospective descriptive study.
SETTING: Gavà 2 Health Centre, located in Barcelona's industrial belt. MATERIAL AND
METHOD: Systematic review of the clinical records for the deaths recorded between May 1993 and March 1998. The following variables were recorded: age, sex, cause and place of death, professional attending patient during terminal phase, use of opiates (type, how they were taken, dosage and length of treatment) and prescribing doctor.
RESULTS: Of the 429 deaths reviewed, 100 (23%) were caused by neoplasm (68% males), with an average age of 69 +/- 3 years. More than half the patients (55%) died at home. In the terminal phase they were mainly attended (69%) by their Primary Care team. 52% of the patients were given opiates, with morphine being the most common (71.1%), followed by codeine (40.3%) and tramadol (17.3%). The general practitioner was the prescribing agent in 69.2% of the cases. 76% of the patients who took codeine did so at infra-therapeutic doses (< 120 mg per day). Similarly, insufficient doses of morphine (< 60 mg per day) were given to half the patients who received it. 21.62% only took it during a period of 5 days or less before death.
CONCLUSIONS: Primary care teams are taking on steadily greater protagonism in caring for terminal cancer patients. Although a large number of these patients are treated with opiates, these are given at often insufficient doses and for too short time periods.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10687223

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  1 in total

1.  [Calculation of the number of terminally ill patients through their use of opioid analgesics and tumor mortality].

Authors:  E Escortell-Mayor; O Larrubia-Muñoz; D Troncoso-Viejo; R Martínez-Martínez; A López-Romero; C de Miguel-Sánchez
Journal:  Aten Primaria       Date:  2006-02-15       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.